186 related articles for article (PubMed ID: 28263085)
1. Exploration of thiaheterocyclic hHDAC6 inhibitors as potential antiplasmodial agents.
Vreese R; Kock C; Smith PJ; Chibale K; D'hooghe M
Future Med Chem; 2017 Mar; 9(4):357-364. PubMed ID: 28263085
[TBL] [Abstract][Full Text] [Related]
2. Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
Nardella F; Halby L; Dobrescu I; Viluma J; Bon C; Claes A; Cadet-Daniel V; Tafit A; Roesch C; Hammam E; Erdmann D; Mairet-Khedim M; Peronet R; Mecheri S; Witkowski B; Scherf A; Arimondo PB
J Med Chem; 2021 Jul; 64(14):10403-10417. PubMed ID: 34185525
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
Soumyanarayanan U; Ramanujulu PM; Mustafa N; Haider S; Fang Nee AH; Tong JX; Tan KSW; Chng WJ; Dymock BW
Eur J Med Chem; 2019 Dec; 184():111755. PubMed ID: 31627059
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
De Vreese R; D'hooghe M
Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
[TBL] [Abstract][Full Text] [Related]
5. Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
Giannini G; Battistuzzi G; Vignola D
Bioorg Med Chem Lett; 2015 Feb; 25(3):459-61. PubMed ID: 25563890
[TBL] [Abstract][Full Text] [Related]
6. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
Chen Y; Lopez-Sanchez M; Savoy DN; Billadeau DD; Dow GS; Kozikowski AP
J Med Chem; 2008 Jun; 51(12):3437-48. PubMed ID: 18494463
[TBL] [Abstract][Full Text] [Related]
7. Repurposing Anticancer Drugs To Tackle Malaria.
Le Govic Y; Houzé S; Papon N
ChemMedChem; 2021 Jul; 16(14):2192-2194. PubMed ID: 33931947
[TBL] [Abstract][Full Text] [Related]
8. Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
Hansen FK; Sumanadasa SD; Stenzel K; Duffy S; Meister S; Marek L; Schmetter R; Kuna K; Hamacher A; Mordmüller B; Kassack MU; Winzeler EA; Avery VM; Andrews KT; Kurz T
Eur J Med Chem; 2014 Jul; 82():204-13. PubMed ID: 24904967
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
Marfurt J; Chalfein F; Prayoga P; Wabiser F; Kenangalem E; Piera KA; Fairlie DP; Tjitra E; Anstey NM; Andrews KT; Price RN
Antimicrob Agents Chemother; 2011 Mar; 55(3):961-6. PubMed ID: 21135175
[TBL] [Abstract][Full Text] [Related]
10. Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
Dow GS; Chen Y; Andrews KT; Caridha D; Gerena L; Gettayacamin M; Johnson J; Li Q; Melendez V; Obaldia N; Tran TN; Kozikowski AP
Antimicrob Agents Chemother; 2008 Oct; 52(10):3467-77. PubMed ID: 18644969
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, antimalarial properties, and SAR studies of alkoxyurea-based HDAC inhibitors.
Hansen FK; Skinner-Adams TS; Duffy S; Marek L; Sumanadasa SD; Kuna K; Held J; Avery VM; Andrews KT; Kurz T
ChemMedChem; 2014 Mar; 9(3):665-70. PubMed ID: 24497437
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of substituted phenalenone analogues as antiplasmodial agents.
Gutiérrez D; Flores N; Abad-Grillo T; McNaughton-Smith G
Exp Parasitol; 2013 Oct; 135(2):456-8. PubMed ID: 23985373
[TBL] [Abstract][Full Text] [Related]
13. A structure-activity relationship study of the antimalarial and antileishmanial activities of nonpeptide macrocyclic histone deacetylase inhibitors.
Guerrant W; Mwakwari SC; Chen PC; Khan SI; Tekwani BL; Oyelere AK
ChemMedChem; 2010 Aug; 5(8):1232-5. PubMed ID: 20533500
[No Abstract] [Full Text] [Related]
14. Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors.
De Vreese R; Depetter Y; Verhaeghe T; Desmet T; Benoy V; Haeck W; Van Den Bosch L; D'hooghe M
Org Biomol Chem; 2016 Feb; 14(8):2537-49. PubMed ID: 26822143
[TBL] [Abstract][Full Text] [Related]
15. Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.
Federico S; Khan T; Fontana A; Brogi S; Benedetti R; Sarno F; Carullo G; Pezzotta A; Saraswati AP; Passaro E; Pozzetti L; Papa A; Relitti N; Gemma S; Butini S; Pistocchi A; Ramunno A; Vincenzi F; Varani K; Tatangelo V; Patrussi L; Baldari CT; Saponara S; Gorelli B; Lamponi S; Valoti M; Saccoccia F; Giannaccari M; Ruberti G; Herp D; Jung M; Altucci L; Campiani G
Eur J Med Chem; 2022 Aug; 238():114409. PubMed ID: 35551034
[TBL] [Abstract][Full Text] [Related]
16. Zinc binding groups for histone deacetylase inhibitors.
Zhang L; Zhang J; Jiang Q; Zhang L; Song W
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):714-721. PubMed ID: 29616828
[TBL] [Abstract][Full Text] [Related]
17. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
18. Beyond the Selective Inhibition of Histone Deacetylase 6.
Rodrigues DA; Thota S; Fraga CA
Mini Rev Med Chem; 2016; 16(14):1175-84. PubMed ID: 27121714
[TBL] [Abstract][Full Text] [Related]
19. Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?
Shen S; Kozikowski AP
ChemMedChem; 2016 Jan; 11(1):15-21. PubMed ID: 26603496
[TBL] [Abstract][Full Text] [Related]
20. Activity of alkoxyamide-based histone deacetylase inhibitors against Plasmodium falciparum malaria parasites.
Dawood WA; Fisher GM; Kinnen FJM; Anzenhofer C; Skinner-Adams T; Alves Avelar L; Asfaha Y; Kurz T; Andrews KT
Exp Parasitol; 2024 Mar; 258():108716. PubMed ID: 38340779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
